This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, a dynamic risk prediction model for multiple myeloma is discussed. Through deep learning, the model is able to adapt to future data, such as emerging treatment modalities and combinations. In addition, global phase 3 results show that bevacizumab with immunotherapy has activity in liver cancer, and D‐VRd is examined as a new standard of care in patients with multiple myeloma.
No takes yet. Share an insight, caveat, or question.
Mary Beth Nierengarten (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: